Apimeds Pharmaceuticals US Inc
AMEX:APUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Apimeds Pharmaceuticals US Inc
AMEX:APUS
|
US |
|
Sleep Number Corp
NASDAQ:SNBR
|
US |
|
P
|
PT Temas Tbk
IDX:TMAS
|
ID |
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
IN |
|
Aeon Financial Service Co Ltd
TSE:8570
|
JP |
|
P
|
People & Technology Inc
KOSDAQ:137400
|
KR |
Apimeds Pharmaceuticals US Inc
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
